[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391(10127):1301-1314.
[3] McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis, 2011, 15(2):223-243, vii-x.
[4] Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int, 2019, 39(12):2214-2229.
[5] Wang S, Zhang K, Tan S, et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies, Mol Cancer, 2021, 20(1):13.
[6] Chen LL, Yang L. Regulation of circRNA biogenesis, RNA Biol, 2015, 12(4):381-388.
[7] Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA, 2013, 19(2):141-157.
[8] Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature, 2013, 495(7441):333-338.
[9] Meng X, Li X, Zhang P, et al. Circular RNA: an emerging key player in RNA world. Brief Bioinform, 2017, 18(4):547-557.
[10] Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet, 2016, 17(5):272-283.
[11] Huang A, Zheng H, Wu Z, et al. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics, 2020, 10(8):3503-3517.
[12] Zhang M, Huang N, Yang X, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis, Oncogene, 2018, 37(13):1805-1814.
[13] Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol, 2015, 22(3):256-264.
[14] Tang X, Ren H, Guo M, et al. Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J, 2021, 19:910-928.
[15] Lei D, Wang T. circSYPL1 promotes the proliferation and metastasis of hepatocellular carcinoma via the upregulation of EZH2 expression by competing with hsa-miR-506-3p. J Oncol, 2022, 2022:2659563.
[16] Sun S, Gao J, Zhou S, et al. A novel circular RNA circ-LRIG3 facilitates the malignant progression of hepatocellular carcinoma by modulating the EZH2/STAT3 signaling. J Exp Clin Cancer Res, 2020, 39(1):252.
[17] Chen Y, Ling Z, Cai X, et al. Activation of YAP1 by N6-methyladenosine-modified circCPSF6 drives malignancy in hepatocellular carcinoma. Cancer Res, 2022, 82(4):599-614.
[18] Liu W, Zheng L, Zhang R, et al. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma. Mol Cancer, 2022, 21(1):72.
[19] Yu Q, Chen W, Li Y, et al. The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis. Bioengineered, 2022, 13(3):4717-4729.
[20] Jiang B, Tian M, Li G, et al. circEPS15 Overexpression in hepatocellular carcinoma modulates tumor invasion and migration. Front Genet, 2022, 13:804848.
[21] Luo YY, Tao KG, Lu YT, et al. Hsa_Circ_0098181 suppresses hepatocellular carcinoma by sponging miR-18a-3p and targeting PPARA. Front Pharmacol, 2022, 13:819735.
[22] Liu H, Lan T, Li H, et al. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR. Theranostics, 2021, 11(3):1396-1411.
[23] Mu Q, Lv Y, Luo C, et al. Research progress on the functions and mechanism of circRNA in cisplatin resistance in tumors. Front Pharmacol, 2021, 12:709324.
[24] Xu J, Wan Z, Tang M, et al. N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling. Mol Cancer, 2020, 19(1):163.
[25] Li Y, Zhang Y, Zhang S, et al. circRNA circARNT2 suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting the miR-155-5p/PDK1 axis. Mol Ther Nucleic Acids, 2020, 23:244-254.
[26] Zhang P, Sun H, Wen P, et al. circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. Mol Ther Nucleic Acids, 2021, 27:293-303.
[27] Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology, 2018, 154(6):1706-1718.e1.
[28] Yoon JH, Lee JM, Lee DH, et al. A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development. Liver Cancer, 2020, 9(5):503-517.
[29] Gupta P, Soundararajan R, Patel A, et al. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. J Hepatol, 2021, 75(1):108-119.
[30] Colli A, Nadarevic T, Miletic D, et al. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma?in adults with chronic liver disease. Cochrane Database Syst Rev, 2021, 4(4):CD013346.
[31] Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol, 2016, 54(12):1296-1305.
[32] Yamamoto Y, Kondo S, Matsuzaki J, et al. Highly sensitive circulating microrna panel for accurate detection of hepatocellular carcinoma in patients with liver disease. Hepatol Commun, 2019, 4(2):284-297.
[33] Li Z, Zhou Y, Yang G, et al. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin Chim Acta, 2019, 492:37-44.
[34] El Sharkawi FZ, Awad MS, Elagawy W, et al. Circular RNAs 0064286 and 0000475: Potential diagnostic biomarkers in hepatocellular carcinoma. Asian Pac J Cancer Prev, 2021, 22(9):3039-3044.
[35] Zhang X, Xu Y, Qian Z, et al. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. Cell Death Dis, 2018, 9(11):1091.
[36] Jiang Z, Shen L, Wang S, et al. Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma. Cancer Med, 2019, 8(17):7278-7287.
[37] Matboli M, Shafei AE, Ali MA, et al. circRNAs (hsa_circ_00156, hsa_circ _000224, and hsa_circ _000520) are novel potential biomarkers in hepatocellular carcinoma. J Cell Biochem, 2018, 120(5):7711-7724.
[38] Sun XH, Wang YT, Li GF, et al. Serum-derived three-circRNA signature as a diagnostic biomarker for hepatocellular carcinoma. Cancer Cell Int, 2020, 20:226.
[39] Yu J, Ding WB, Wang MC, et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: A large-scale, multicenter study. Int J Cancer, 2020, 146(6):1754-1763.
[40] Zhang Y, Li J, Cui Q, et al. Circular RNA hsa_circ_0006091 as a novel biomarker for hepatocellular carcinoma. Bioengineered, 2022, 13(2):1988-2003.
[41] Liu R, Li Y, Wu A, et al. Identification of plasma hsa_circ_0005397 and combined with serum afp, afp-l3 as potential biomarkers for hepatocellular carcinoma. Front Pharmacol, 2021, 12:639963.
[42] Qiao GL, Chen L, Jiang WH, et al. Hsa_circ_0003998 may be used as a new biomarker for the diagnosis and prognosis of hepatocellular carcinoma. Onco Targets Ther, 2019, 12:5849-5860.
[43] Zhang X, Zhou H, Jing W, et al. The circular RNA hsa_circ_0001445 regulates the proliferation and migration of hepatocellular carcinoma and May Serve as a diagnostic biomarker. Dis Markers, 2018, 2018:3073467. |
